Feedback
Settings

Settings

Goto Application

1,932,836 results
Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 193,284
1.WO/2026/101967SYNTHESIS OF RENEWABLE TEREPHTHALATES AND AROMATIC DIISOCYANATES FROM MONOSACCHARIDES
WO - 15.05.2026
Int.Class C07C 67/32
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
67Preparation of carboxylic acid esters
30by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
317by splitting-off hydrogen or functional groups; by hydrogenolysis of functional groups
32Decarboxylation
 Appl.No PCT/US2025/054114 Applicant THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Inventor HALLORAN, Matthew
is alkyl:
2.WO/2026/102147TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS
WO - 15.05.2026
Int.Class C07D 417/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
417Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/196
14containing three or more hetero rings
 Appl.No PCT/US2025/054404 Applicant TREELINE BIOSCIENCES, INC. Inventor HORN, Evan J.
protein. These compounds are useful, for example, for treating a cancer in a subject (e.g., a human). This disclosure also provides compositions comprising the compounds of Formula (I), (II), (III), (IV), (V), or (VI), or pharmaceutically acceptable salts thereof, provided herein as well as methods of using and making the same.
3.WO/2026/102297ANTIBODY OLIGONUCLEOTIDE CONJUGATES FOR TREATING DISEASE
WO - 15.05.2026
Int.Class A61K 31/7105
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7088Compounds having three or more nucleosides or nucleotides
7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
 Appl.No PCT/US2025/054619 Applicant STUART, William Inventor STUART, William
Disclosed herein are antibody-oligonucleotide conjugates, pharmaceutical compositions, and methods for treating Sickle Cell Disease. The disclosure contemplates compositions and methods capable of binding a human hematopoietic stem cell marker conjugated to an oligonucleotide capable of hybridizing a target sequence. In some embodiments, the target sequence is a BCL11A transcript sequence. In some embodiments of the disclosure, the antibody-oligonucleotide conjugate promotes antisense- and/or RNA interference-mediated inhibition of BCL11A.
4.WO/2026/102432HUMAN ANTIBODIES TO MARBURG VIRUS AND METHODS OF USE THEREFOR
WO - 15.05.2026
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
 Appl.No PCT/US2025/054898 Applicant VANDERBILT UNIVERSITY Inventor CROWE, JR., James E.
The present disclosure is directed to antibodies binding to and neutralizing Marburg Virus and methods for use thereof.
5.WO/2026/099687CROSS-LINKABLE ELASTOMERIC COMPOSITION AND TIRE
WO - 15.05.2026
Int.Class C07D 309/40
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
309Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
34having three or more double bonds between ring members or between ring members and non-ring members
36with oxygen atoms directly attached to ring carbon atoms
40Oxygen atoms attached in positions 3 and 4, e.g. maltol
 Appl.No PCT/IB2025/060918 Applicant PIRELLI TYRE S.P.A. Inventor GIANNINI, Luca
This invention relates to: a cross-linkable elastomeric composition comprising an unsaturated heterocyclic compound; a process for preparing an elastomeric compound; a tire component comprising the aforementioned elastomeric compound; and a tire for vehicle wheels comprising at least the aforementioned tire component.
6.WO/2026/099807TYPE-I INTERFERON RESPONSE AND EXHAUSTION GENE SIGNATURE AS A BIOMARKER FOR CANCER IMMUNOTHERAPY
WO - 15.05.2026
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
 Appl.No PCT/IB2025/061397 Applicant UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION Inventor FERRIS, Robert, Louis
Provided herein is a method of treating a patient having a tumor, including determining whether one or more immune cells from the patient express an exhaustion phenotype and administering to the patient one or more therapeutic compositions, wherein: the therapeutic composition includes either one or more checkpoint inhibitors (ICIs) in an amount effective to treat the tumor when the one or more immune cells express the exhaustion phenotype or one or more compounds effective to prime the one or more immune cells to respond to one or more ICIs when the one or more cells do not express the exhaustion phenotype.
7.WO/2026/099867SUSTAINABLE ANTIFREEZE COATINGS BY PEPTIDE SELF-ASSEMBLY
WO - 15.05.2026
Int.Class C09D 5/16
CCHEMISTRY; METALLURGY
09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
DCOATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
5Coating compositions, e.g. paints, varnishes or lacquers, characterised by their physical nature or the effects produced; Filling pastes
16Anti-fouling paints; Underwater paints
 Appl.No PCT/IL2025/051001 Applicant YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. Inventor RECHES, Meital
The technology disclosed in the application concerns antifreeze and anti-ice peptidic films.
8.WO/2026/099897NOVEL LINKERS AND ITS PREPARATION METHODS THEREOF
WO - 15.05.2026
Int.Class C07D 207/452
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
207Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
02with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
44having three double bonds between ring members or between ring members and non-ring members
444having two doubly-bound oxygen atoms directly attached in positions 2 and 5
448with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
452with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
 Appl.No PCT/IN2025/051760 Applicant ZYDUS LIFESCIENCES LIMITED Inventor IYER, Pravin
The present invention relates to a novel linker for Antibody-drug conjugates (ADCs), Peptide- drug conjugates (PDCs) and a preparation method for it, wherein the linker's one end can selectively and covalently link a targeting substance, and its other end can covalently link to a small molecule compound or a cytotoxic payload. The linkers of the present invention can be used to prepare an antibody drug conjugate, and it can be used for various applications including anticancer activity and other medicinal uses.
9.WO/2026/100692METHANOL SYNTHESIS CATALYST AND METHOD FOR PRODUCING METHANOL SYNTHESIS CATALYST
WO - 15.05.2026
Int.Class B01J 27/24
BPERFORMING OPERATIONS; TRANSPORTING
01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
27Catalysts comprising the elements or compounds of halogens, sulfur, selenium, tellurium, phosphorus or nitrogen; Catalysts comprising carbon compounds
24Nitrogen compounds
 Appl.No PCT/JP2025/039150 Applicant AGC INC. Inventor TODA, Yoshitake
N. In general formula (1), A is at least one metal selected from among palladium, cobalt, nickel and rhodium, and 0.02<x<2.
10.WO/2026/101157BIOSENSOR SYSTEM FOR MONITORING EPOR DIMER FORMATION INDUCED BY LIGAND, AND TARGET LIGAND DETECTION METHOD USING SAME
WO - 15.05.2026
Int.Class G01N 33/74
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
74involving hormones
 Appl.No PCT/KR2025/017831 Applicant DAEGU GYEONGBUK INSTITUTE OF SCIENCE AND TECHNOLOGY Inventor LEE, Chang Hun
The present invention relates to a biosensor system for monitoring EPOR dimer formation by ligands and a target ligand detection method using same, wherein EPOR dimer formation by ligand binding can be rapidly and sensitively monitored using a fusion protein in which the EPOR ectodomain and a split fluorescent protein are fused. In addition, it is possible to monitor EPOR dimer formation by ligands and detect target ligands in vitro, and thus the complexity and duration of cell-based assays can be reduced, and high-speed screening can be easily applied. In addition, by measuring the reference fluorescence of a reference fluorescent protein together along with a signal fluorescence and comparing the reference fluorescence and signal fluorescence, accurate and quantitative analysis can be performed regardless of changes in measurement environment or variations in protein concentration.
# -